Summary | EzMTX

High-dose methotrexate (HDMTX) is a key treatment for pediatric malignancies. However, in low-resource settings, clinicians face challenges due to the lack of accessible MTX monitoring tools, making it difficult to track toxicities and optimize treatment. To address this, we designed a low-cost, portable assay for urine-based MTX monitoring: the EzMTX assay. We leverage MTX’s inhibition of dihydrofolate reductase to produce a simple, clinically relevant readout, then integrate this with a digital app that quantifies results for clinical use. Our assay empowers safer and effective HDMTX treatment and supports equitable global pediatric cancer care.